关于使用部分闲置募集资金进行现金管理进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 现金管理受托方：兴业银行股份有限公司台州临海支行（以下简称"兴 业银行"） 已履行的审议程序：奥锐特药业股份有限公司（以下简称"公司"或"奥 锐特"）于 2024 年 8 月 27 日召开第三届董事会第八次会议及第三届监事会第八 次会议分别审议通过了《关于使用部分闲置募集资金进行现金管理的议案》，同 意公司及子公司使用闲置募集资金不超过人民币 3 亿元进行现金管理，上述额度 可以滚动使用，自第三届董事会第八次会议审议通过之日起 12 个月内有效，并 授权公司管理层在上述额度内行使决策权，具体事项由公司财务部负责组织实施。 具体内容详见公司于 2024 年 8 月 29 日披露于上海证券交易所网站 （www.sse.com.cn）的《奥锐特药业股份有限公司关于使用部分闲置募集资金进 行现金管理的公告》（公告编号：2024-047）。 特别风险提示：尽管本次公司选择的现金管理产品属于保本型理财产品， 但金融市场受宏观经济、 ...

证券代码：605116 证券简称：奥锐特 公告编号：2024-060 债券代码：111021 债券简称：奥锐转债 奥锐特药业股份有限公司 单位：人民币万元 特此公告。 奥锐特药业股份有限公司董事会 2024 年 11 月 13 日 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 奥锐特药业股份有限公司（以下简称"公司"或"奥锐特"）于 2024 年 8 月 27 日召开第三届董事会第八次会议及第三届监事会第八次会议分别审议通过 了《关于使用部分闲置募集资金进行现金管理的议案》，同意公司及子公司使用 闲置募集资金不超过人民币 3 亿元进行现金管理，上述额度可以滚动使用，自第 三届董事会第八次会议审议通过之日起 12 个月内有效，并授权公司管理层在上 述额度内行使决策权，具体事项由公司财务部负责组织实施。具体内容详见公司 于 2024 年 8 月 29 日披露于上海证券交易所网站（www.sse.com.cn）的《奥锐特 药业股份有限公司关于使用部分闲置募集资金进行现金管理的公告》（公告编号： 2024-047）。 2024 年 ...

Investment Rating - The report maintains a "Buy" rating for the company [3][4]. Core Views - The company shows improved profitability, with a revenue of 1.088 billion yuan for Q1-Q3 2024, representing a year-on-year growth of 17.97%. The net profit attributable to the parent company reached 284 million yuan, up 22.04% year-on-year. However, Q3 revenue saw a decline of 3.30% year-on-year, and net profit dropped by 30.33% due to high base effects from the previous year and financial costs [3][4]. - The gross margin for Q1-Q3 2024 was 58.22%, an increase of 2.58 percentage points year-on-year, with Q3 gross margin at 60.68%, reflecting continuous improvement driven by high-margin product sales [3]. - The company is focusing on enhancing its specialty raw materials and formulation business, with significant progress in its peptide and oligonucleotide platform capabilities. The company is also expanding its international marketing system [3][4]. Financial Summary - For 2024E, the company forecasts revenue of 1.566 billion yuan, with a year-on-year growth of 24.1%. The net profit is projected to be 393 million yuan, reflecting a growth of 35.9% [8][9]. - The earnings per share (EPS) estimates for 2024, 2025, and 2026 are 0.97 yuan, 1.25 yuan, and 1.56 yuan, respectively [3][9]. - The target price is set at 29.10 yuan, based on a price-to-earnings (PE) ratio of 23 times for 2025 [3][4]. Market Data - The current stock price is 21.86 yuan, with a market capitalization of 8.879 billion yuan. The stock has traded within a range of 18.40 to 26.77 yuan over the past 52 weeks [5][6]. - The company has a net asset value per share of 5.58 yuan, with a price-to-book (P/B) ratio of 3.9 at the current price [6].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1]. Core Views - The company has demonstrated steady growth in revenue and profit, with the upcoming launch of Semaglutide expected to drive further growth. The small nucleic acid business is also entering a harvest phase, injecting new growth momentum [1]. - The company's revenue and profit growth in the first three quarters of 2024 is primarily attributed to the continued ramp-up of Dydrogesterone preparations and the recovery in demand for high-margin raw materials [1]. - The report anticipates that the company's performance will continue to maintain a steady growth trend due to the increasing volume of high-margin raw materials and the ongoing production ramp-up of Semaglutide and other peptide raw materials [1]. Financial Summary - **Revenue (in million CNY)**: - 2022A: 1008.08 (25.48% growth) - 2023A: 1262.53 (25.24% growth) - 2024E: 1528.23 (21.04% growth) - 2025E: 1873.56 (22.60% growth) - 2026E: 2287.04 (22.07% growth) [1]. - **Net Profit (in million CNY)**: - 2022A: 210.96 - 2023A: 289.42 - 2024E: 383.24 - 2025E: 500.91 - 2026E: 655.39 [1]. - **Earnings Per Share (in CNY)**: - 2022A: 0.52 - 2023A: 0.71 - 2024E: 0.94 - 2025E: 1.23 - 2026E: 1.61 [1]. - **Price-to-Earnings (P/E) Ratio**: - 2022A: 48.67 - 2023A: 35.48 - 2024E: 26.79 - 2025E: 20.50 - 2026E: 15.67 [1]. - **Price-to-Book (P/B) Ratio**: - 2022A: 6.13 - 2023A: 5.22 - 2024E: 4.48 - 2025E: 3.97 - 2026E: 3.46 [1]. Quarterly Performance - The company reported a revenue of 1.088 billion CNY in Q1-Q3 2024, representing a year-on-year growth of 17.97%. The net profit for the same period was 284 million CNY, with a year-on-year increase of 22.04% [1][2]. - The gross margin remained stable, and the increase in revenue led to a decrease in expense ratios, with continuous investment in R&D [1]. Future Outlook - The report suggests that the company is expected to continue its growth trajectory, driven by the ramp-up of Dydrogesterone tablets and a rich pipeline of projects, including the expansion of production capacity for peptides and small nucleic acid drugs [1].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 28.00, compared to the last closing price of 23.68 [1]. Core Views - The company's Q3 revenue and profit showed a slight decline quarter-on-quarter, but overall performance met market expectations. For Q3 2024, the company achieved revenue of 3.58 billion yuan, a decrease of 9.46% quarter-on-quarter, and a net profit of 0.95 billion yuan, an increase of 10.53% quarter-on-quarter [2][4]. - The year-to-date revenue for the first three quarters of 2024 reached 10.88 billion yuan, representing a year-on-year increase of 17.97%, while the net profit attributable to shareholders was 2.84 billion yuan, up 22.04% year-on-year [2][4]. - The decline in revenue and profit is attributed to a decrease in trade sales and an increase in financial expenses due to foreign exchange losses and convertible bond costs [2][4]. - The gross margin for Q3 2024 was 60.68%, down 3.69 percentage points year-on-year, while the net profit margin was 26.62%, down 10.12 percentage points year-on-year [2][4]. Summary by Sections Financial Performance - For Q3 2024, the company reported a revenue of 3.58 billion yuan and a net profit of 0.95 billion yuan, with a year-to-date revenue of 10.88 billion yuan and a net profit of 2.84 billion yuan [2][4]. - The company forecasts revenues of 15.38 billion yuan, 18.50 billion yuan, and 22.73 billion yuan for 2024, 2025, and 2026 respectively, with net profits of 3.91 billion yuan, 5.08 billion yuan, and 6.60 billion yuan for the same years [2][4]. Business Development - The company is actively promoting an integrated model of "active pharmaceutical ingredients + formulations," with the Dydrogesterone tablet expected to accelerate sales growth. The product was approved for sale in June 2023 and has been listed in 30 provinces and cities, with sales revenue of 92.48 million yuan in H1 2024 [2][4]. - The company has submitted registration applications for additional products, expecting to receive approvals for 3-5 new products annually starting in 2026 [2][4]. Valuation Metrics - The report provides projected earnings per share (EPS) of 0.96 yuan, 1.25 yuan, and 1.63 yuan for 2024, 2025, and 2026 respectively, with corresponding price-to-earnings (PE) ratios of 25, 19, and 15 [2][4].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1][10]. Core Views - The company has experienced rapid growth in the first three quarters of 2024, with a revenue of 1.088 billion yuan, representing a year-on-year increase of 17.97%. The net profit attributable to the parent company reached 284 million yuan, up 22.04% year-on-year, and the non-recurring net profit was 282 million yuan, reflecting a significant increase of 44.5% [3][4]. - The company's formulation business is expanding quickly, with the recent approval of various products expected to contribute to future growth. The company is enhancing its distribution network and academic team to improve market penetration [4][5]. - Due to significant export revenue and exchange rate fluctuations, the company's profit forecast has been adjusted downward for 2024-2026, with expected net profits of 391 million, 510 million, and 678 million yuan respectively [3][4]. Financial Summary - For the first three quarters of 2024, the company reported a gross margin of 58.22% (up 2.58 percentage points) and a net margin of 26.08% (up 0.85 percentage points) [3]. - The company's revenue and profit projections for the next few years indicate a strong growth trajectory, with expected revenues of 1.657 billion yuan in 2024, 2.184 billion yuan in 2025, and 2.710 billion yuan in 2026, reflecting year-on-year growth rates of 31.2%, 31.8%, and 24.1% respectively [6][7]. - The company's P/E ratios are projected to decrease from 24.6 in 2024 to 14.2 in 2026, indicating an attractive valuation as earnings grow [3][6].

法律意见书 国浩律师（杭州）事务所 国浩律师（杭州）事务所 关 于 奥锐特药业股份有限公司 2022 年限制性股票激励计划 第二个解除限售期解除限售及调整回购价 格相关事项 的法律意见书 地址：杭州市上城区老复兴路白塔公园 B 区 2 号、15 号国浩律师楼 邮编：310008 GrandallBuilding,No.2＆No.15,BlockB,BaitaPark,OldFuxingRoad,Hangzhou,Zhejiang310008,China 电话/Tel：（+86）（571）85775888 传真/Fax：（+86）（571）85775643 电子邮箱/Mail：grandallhz@grandall.com.cn 网址/Website：http://www.grandall.com.cn 二〇二四年十月 法律意见书 国浩律师（杭州）事务所 国浩律师（杭州）事务所 关 于 奥锐特药业股份有限公司 2022 年限制性股票激励计划 第二个解除限售期解除限售及调整回购价格相关事 项 的法律意见书 致：奥锐特药业股份有限公司 根据奥锐特药业股份有限公司（以下简称"奥锐特"或"公司"）与国浩律 师（杭州）事 ...

Financial Performance - Revenue for the third quarter was 357.67 million yuan, a decrease of 3.30% year-over-year[2] - Net profit attributable to shareholders of the listed company for the third quarter was 95.20 million yuan, a decrease of 30.33% year-over-year[2] - Total operating revenue for the first three quarters of 2024 reached 1,088,322,409.18 RMB, a 17.97% increase compared to 922,528,504.47 RMB in the same period of 2023[14] - Net profit attributable to the parent company's shareholders in the first three quarters of 2024 was 283,794,989.04 RMB, up 22.03% from 232,546,693.99 RMB in the same period of 2023[17] - Basic earnings per share for the third quarter were 0.24 yuan, a decrease of 27.27% year-over-year[4] - Diluted earnings per share for the third quarter were 0.22 yuan, a decrease of 33.33% year-over-year[4] - Basic earnings per share for the first three quarters of 2024 were 0.70 RMB, up from 0.57 RMB in the same period of 2023[17] - Weighted average return on equity (ROE) for the third quarter was 4.49%, a decrease of 3.72 percentage points year-over-year[4] - The decrease in net profit was mainly due to the absence of gains from the disposal of subsidiaries compared to the same period last year[7] Assets and Liabilities - Total assets as of the end of the reporting period were 3.69 billion yuan, an increase of 43.36% compared to the end of the previous year[4] - Total assets as of the end of Q3 2024 reached 3,690,915,800.95 RMB, a 43.37% increase compared to 2,574,610,570.52 RMB at the end of Q3 2023[14] - Total liabilities as of the end of Q3 2024 stood at 1,422,707,189.31 RMB, a significant increase from 607,025,380.82 RMB at the end of Q3 2023[14] - Total equity attributable to the parent company's shareholders as of the end of Q3 2024 was 2,268,208,611.64 RMB, a 15.28% increase from 1,967,585,189.70 RMB at the end of Q3 2023[14] - The increase in total assets was primarily due to the receipt of funds from convertible bonds and continuous investment in construction projects[8] Cash Flow - Net cash flow from operating activities for the period was 301.49 million yuan, an increase of 4.36% year-over-year[4] - Net cash flow from operating activities increased to 301,485,784.55 RMB, a 4.4% rise from 288,896,804.19 RMB in the previous year[18] - Total cash inflows from operating activities rose to 1,301,821,169.39 RMB, a 31.4% growth from 990,541,950.70 RMB in 2023[18] - Cash inflows from investment activities grew significantly to 232,663,738.42 RMB, a 259.3% increase from 64,749,351.07 RMB in 2023[18] - Cash outflows for investment activities surged to 825,521,567.15 RMB, a 316.4% jump from 198,260,528.31 RMB in the previous year[18] - Net cash flow from financing activities skyrocketed to 736,301,362.00 RMB, a massive increase from 3,004,165.97 RMB in 2023[19] - The company's cash and cash equivalents balance at the end of the period reached 856,975,209.89 RMB, up 69.8% from 504,574,923.07 RMB in 2023[19] - The company invested 438,220,122.15 RMB in fixed assets, intangible assets, and other long-term assets, a 125.8% increase from 194,045,508.31 RMB in 2023[18] Shareholder Information - Total number of ordinary shareholders at the end of the reporting period is 8,992[9] - Zhejiang Tongben Investment Co., Ltd. holds 153,583,200 shares, accounting for 37.81% of the total shares[9] - Chu Yizhou holds 112,294,800 shares, accounting for 27.65% of the total shares[9] - Liu Meihua holds 16,513,200 shares, accounting for 4.07% of the total shares[9] - Qiu Peijing holds 11,178,000 shares, accounting for 2.75% of the total shares[9] - Tiantai Borong Investment Partnership holds 9,907,200 shares, accounting for 2.44% of the total shares[9] - Qiu Weihong holds 9,841,500 shares, accounting for 2.42% of the total shares, with 1,950,000 shares pledged[9] - Li Jianwen holds 6,984,000 shares, accounting for 1.72% of the total shares[9] - Tiantai Boen Investment Management Partnership holds 6,606,000 shares, accounting for 1.63% of the total shares[9] - China Bank Co., Ltd. - Huaxia Industry Prosperity Mixed Securities Investment Fund holds 4,987,442 shares, accounting for 1.23% of the total shares[9] Expenses and Costs - R&D expenses for the first three quarters of 2024 amounted to 105,370,544.25 RMB, a 10.01% increase compared to 95,784,972.98 RMB in the same period of 2023[16] - Operating costs for the first three quarters of 2024 were 764,635,750.47 RMB, a 10.40% increase compared to 692,605,370.46 RMB in the same period of 2023[16] - Sales expenses for the first three quarters of 2024 were 89,328,569.25 RMB, a 32.88% increase compared to 67,241,436.28 RMB in the same period of 2023[16] - The company's financial expenses showed a net income of 11,853,382.66 RMB in the first three quarters of 2024, compared to 7,357,470.96 RMB in the same period of 2023[16] - Cash outflows for purchasing goods and services jumped to 531,081,368.60 RMB, up 57.8% from 336,469,567.06 RMB in 2023[18] Non-Recurring Items - Non-recurring gains and losses for the period amounted to 744,316.34 yuan[6] Sales and Revenue - Sales revenue from goods and services received in cash increased to 1,134,032,793.23 RMB, up 29.3% compared to 876,966,095.44 RMB in the same period last year[18] - Tax refunds received surged to 128,340,307.36 RMB, a 109.5% increase from 61,258,280.88 RMB in the previous year[18]

证券代码：605116 证券简称：奥锐特 公告编号：2024-057 债券代码：111021 债券简称：奥锐转债 奥锐特药业股份有限公司 第三届董事会第九次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 表决结果：同意 7 票，反对 0 票，弃权 0 票。关联董事彭志恩、李金亮 已回避表决。 奥锐特药业股份有限公司（以下简称"公司"）第三届董事会第九次会议于 2024 年 10 月 24 日在公司会议室以现场结合通讯方式召开。本次会议的通知于 2024 年 10 月 21 日以邮件方式送达全体董事、监事及高级管理人员，会议由董 事长彭志恩召集并主持，应到董事 9 人，实到董事 9 人。 本次会议的通知、召开、表决程序符合《中华人民共和国公司法》《奥锐特 药业股份有限公司章程》以及相关法律、法规的有关规定，会议形成的决议合 法有效。 二、董事会会议审议情况 1、审议通过《关于公司 2022 年限制性股票激励计划第二个解除限售期解 除限售条件成就的议案》 根据《上市公司股权激励管理办法》、公司 ...

证券代码：605116 证券简称：奥锐特 公告编号：2024-058 债券代码：111021 债券简称：奥锐转债 本次会议的通知、召开、表决程序符合《中华人民共和国公司法》《奥锐特 药业股份有限公司章程》以及相关法律、法规的有关规定，会议形成的决议合法 有效。 二、监事会会议审议情况 参会监事对相关议案进行了充分讨论，以现场结合通讯方式通过以下议案， 形成决议如下： （一）审议通过《关于公司 2022 年限制性股票激励计划第二个解除限售期 解除限售条件成就的议案》 第三届监事会第九次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、 监事会会议召开情况 奥锐特药业股份有限公司（以下简称"公司"）第三届监事会第九次会议于 2024 年 10 月 24 日在公司会议室以现场结合通讯方式召开。本次会议的通知于 2024 年 10 月 21 日以邮件方式送达全体监事及相关人员，会议由监事会主席金 平召集并主持，应到监事 3 人，实到监事 3 人。 奥锐特药业股份有限公司 经审议，监事会认为：鉴于公司 2022 年度限制 ...